Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial - Trial NCT06362291
Access comprehensive clinical trial information for NCT06362291 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 340 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University First Hospital
Timeline & Enrollment
N/A
Aug 01, 2023
Apr 30, 2025
Primary Outcome
The clinically significant prostate cancer (csPCa) detection rate for targeted biopsy (TB) and TB combined with systematic biopsy (SB)
Summary
The goal of this clinical trial is to compare the cancer detection rates of MRI artificial
 intelligence-guided cTB (AI-cTB) and routine cTB, and explore the added value of using AI for
 the guidance of cTB. The main questions it aims to answer are:
 
 Does AI-cTB promote the accurate diagnosis and treatment of prostate cancer? What's the value
 of prostate MRI artificial intelligence assistant diagnosis system in developing the best
 scheme of prostate biopsy? What's the value of prostate MRI artificial intelligence assistant
 diagnosis system in predicting the pathological results of prostate targeted biopsy?
 
 Researchers will compare the cancer detection rates of AI-cTB and routine cTB to explore the
 added value of using AI for the guidance of cTB.
 
 Participants will:
 
 Receive AI-cTB or routine cTB.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06362291
Non-Device Trial